Applications of (S)-3-Amino-4-(2,4-Dichlorophenyl)Butanoic Acid Hydrochloride in Industrial Manufacturing

As a specialized manufacturer of (S)-3-Amino-4-(2,4-Dichlorophenyl)Butanoic Acid Hydrochloride, our production standards and technical expertise enable reliable supply and consistent quality to pharmaceutical and fine chemical industries. Below, we highlight established industrial application scenarios, focusing on regulated markets and downstream users with stringent quality protocols.

1. Active Pharmaceutical Ingredient (API) Intermediate for Antiepileptic Drug Synthesis

This raw material serves as a critical chiral intermediate in the production of licensed antiepileptic APIs, specifically as a key precursor during the synthesis stage for Lacosamide manufacturing. Regulatory authorities require specialized tracking, traceability, and validation of intermediates throughout the drug production lifecycle. Synthesizing this core building block in-house ensures tighter process control, batch consistency, and streamlined documentation for downstream pharmaceutical partners.

Industry compliance standards

• EU GMP Part II for API intermediates
• 21 CFR Part 211 for US drug manufacturing
• ICH Q7 Good Manufacturing Practice
• Relevant monographs in European Pharmacopoeia (Ph. Eur.)

Typical usage ratio

• Stage-specific: 0.75–1.10 mole equivalents per targeted API formation, adjusted based on route optimization and yield requirements for final Lacosamide synthesis

Downstream process integration

• Introduced after the initial condensation and ring-closure, entering as a resolved enantiomer during the key carbon chain extension step
• Serves as the controlled input for final API cyclization and deprotection reactions

Final product types

• Bulk Lacosamide (API) for global pharmaceutical companies
• Finished antiepileptic solid oral dosage forms

2. Reference Compound and Impurity Marker for Analytical Labs

Analytical laboratories in the pharmaceutical sector use this compound as a reference standard for method development, impurity profiling, and stability studies. Its verified chiral purity and consistent supply are essential for qualified laboratories conducting validation, release testing, and batch-to-batch quality comparisons of formulated drugs. Use as a traceable impurity marker also supports regulatory submissions and pharmacopoeial compliance evaluations.

Industry compliance standards

• USP Chapter <467> Residual Solvents
• ISO/IEC 17025 accreditation for analytical laboratories
• WHO Good Laboratory Practice (GLP) guidelines
• European Pharmacopoeia reference substance standards

Typical usage ratio

• 5–50 μg/mL in calibration mixtures and impurity panels, adjusted per assay sensitivity and method validation parameters

Downstream process integration

• Prepared and dispensed in pre-weighed vials as certified reference material for HPLC, GC, and LC-MS analytical methods
• Applied during method development for both chiral and achiral separation analysis

Final product types

• Pharmaceutical impurity standards
• Calibration sets and verification samples for drug formulation labs

3. Fine Chemical Synthesis Intermediate for Chiral Building Blocks

This raw material enters custom manufacturing supply chains as an advanced intermediate for producing a range of enantiomerically pure building blocks required in asymmetric synthesis. Specialty fine chemical manufacturers rely on the stereochemical integrity and analytical traceability of the supplied material, especially for applications involving contract synthesis of pharmaceutical intermediates and advanced R&D targets.

Industry compliance standards

• ISO 9001:2015 Quality Management System for chemical production
• REACH (EC 1907/2006) for chemical safety in the EU
• IPEC-PQG GMP guideline for excipient production
• Custom regulatory filings for non-clinical intermediates

Typical usage ratio

• 0.8–1.2 parts by mole in chiral auxiliary insertions, adjusted according to downstream product requirements and stereoselectivity targets

Downstream process integration

• Charged during the mid-phase of enantioselective synthesis steps in multi-stage chemical routes
• Employed as a chiral synthon for further functional group modifications

Final product types

• Chiral auxiliaries, amino acid derivatives, and non-commercial API intermediates
• Custom fine chemicals for medicinal chemistry projects

4. Process Development and Scale-Up for Pharmaceutical Contract Manufacturing Organizations (CMOs)

Contract manufacturing organizations (CMOs) utilize this raw material for process optimization, scale-up trials, and validation runs necessary to establish commercial manufacturing parameters for new drug entities. Its documented impurity profile and batch reproducibility assist process engineers and QC teams in risk assessments, technology transfers, and in meeting client-specific CMC submission requirements.

Industry compliance standards

• US FDA Quality System Regulation (QSR) 21 CFR Part 820 for CMOs handling pharmaceutical substances
• ICH Q11 Development and Manufacture of Drug Substances
• PIC/S GMP Guide for process validation
• Client-specific technical agreements for CMO projects

Typical usage ratio

• Determined by client-provided route, typically 0.85–1.05 molar equivalents per scale-up batch, adjusted in pilot plant and full commercial runs to optimize conversion and minimize impurity carryover

Downstream process integration

• Fed into validated reactors at controlled rates during kilo-lab and pilot plant runs
• Tracked with in-process analytical controls for intermediate quality assessment

Final product types

• Validated cGMP pharmaceutical intermediates
• Pilot and commercial batches of APIs under confidentiality agreements